( SAN DIEGO--(BUSINESS WIRE)--Apr 17 200...)ArteFill 5-Year Data to Be Presented at American Society for,Aesthetic Plastic Surgery Annual Meeting,Health

SAN DIEGO--(BUSINESS WIRE)--Apr 17, 2007 - Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company focused on developing, manufacturing and commercializing a new category of aesthetic injectable products for men and women, today announced that the final 5-year safety and efficacy data for ArteFill(R), the Company's FDA-approved non-resorbable injectable dermal filler will be presented at the national meeting of the American Society for Aesthetic Plastic Surgery (ASAPS) on April 20, 2007 in New York City by Steven R. Cohen, MD, FACS, Clinical Professor, Division of Plastic Surgery, University of California, San Diego, School of Medicine and lead ArteFill clinical investigator. The session will also include a live patient workshop to demonstrate the proper techniques in the treatment of nasolabial folds (smile lines).

The 5-year clinical data represents the culmination of a significant follow-up study of 145 patients who were treated with ArteFill in the Company's U.S. clinical trial. The Company has submitted the data to the FDA in order to enhance the product labeling of ArteFill.

About ArteFill(R)

ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of wrinkles known as smile lines or nasolabial folds. The unique microspheres in ArteFill are not absorbed by the body and therefore provide the first-of-its-kind permanent support for long-lasting wrinkle correction in one to two treatments.

ArteFill was approved by the FDA in October 2006 based on data from the Company's 12-month controlled, randomized, double-masked, multi-center U.S. clinical trial, which compared outcomes for patients treated with ArteFill with those of patients treated with the leading bovine collagen-based filler. At the 6-month evaluation, which was the primary efficacy evaluation period for the clinical trial, the wrinkle correction in patients treated with Arte
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes